Pharmalittle: We’re reading about an FDA hold on an Amgen obesity drug, imported Canadian drugs, and more
The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight loss drug market,
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...
Hosted on MSN45m
Amgen Shrugs Off A Surprise Setback For One Of Its Obesity DrugsAmgen stock rose early Wednesday, though the biotech behemoth said the FDA placed one of its obesity treatments on clinical ...
Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...
Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.
Shares of the company began plunging in November, but its overall strength should set the stock up for some serious potential ...
Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback